علاج اعتلال الشبكية السكري في المرض التكاثري عالي الخطورة أو الجلوكوما الوعائية الجديدة

References

1. When new vessels are accompanied by vitreous hemorrhage, or when NVD occupy greater than or equal to about one-quarter to one-third disc area, even in the absence of vitreous hemorrhage, PDR is considered high-risk.
2. Patients with neovascular glaucoma or high-risk PDR should receive prompt treatment with anti-VEGF agents and PRP (see Care Process and Glossary).
3. Most patients with high-risk PDR should receive PRP expeditiously, because it usually induces regression of retinal neovascularization.
4. The DRCR.net study Protocol S that examined patients with PDR primarily has demonstrated that a series of anti-VEGF injections (ranibizumab was used in this protocol) is noninferior to PRP at 2 years.
5. Anti-VEGF treatment alone could be considered for patients with reliable follow-up.